Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity
T25593	Labetuzumab govitecan	1469876-18-3	98%
T25593	Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.
T36646	Trastuzumab deruxtecan	1826843-81-5	98%
T36646	Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of...
T39595	Disitamab vedotin	2136633-23-1	98%
T39595	Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ...
T9914	Vedolizumab	943609-66-3	98%
T9914	Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis.
T9925	Ofatumumab	679818-59-8	98%
T9925	Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
T9928	Ranibizumab	347396-82-1	98%
T9928	Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
T9927	Panitumumab	339177-26-3	98%
T9927	Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
T9922	Matuzumab	339186-68-4	98%
T9922	Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...
T38105	Ixekizumab	1143503-69-8	98%
T38105	Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL...
T38951	Isatuximab	1461640-62-9	98%
T38951	Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu...
T11126	Durvalumab	1428935-60-7	98%
T11126	Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n...
T37535	Camrelizumab	1798286-48-2	98%
T37535	Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhib...
T36647	Trastuzumab emtansine	1018448-65-1	98%
T36647	Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit...
T12706	Reslizumab	241473-69-8	98%
T12706	Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T39057	Rozanolixizumab	1584645-37-3	98%
T39057	Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing path...
T9923	Nimotuzumab	828933-51-3	98%
T9923	Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T39730	Datopotamab deruxtecan	2238831-60-0	98%
T39730	Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a ...
T27970	Mabuterol free base	56341-08-3	98%
T27970	Mabuterol is a selective agonist of β2 adrenoreceptor with no beta 1-stimulation. Mabuterol inhibited the positive inotropic effect of isoprenaline at 10(-7) g/m...
T38362	Guselkumab	1350289-85-8	98%
T38362	Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of ...
T13666	Dupilumab	1190264-60-8	98%
T13666	Dupilumab (RegN-668) can inhibit IL-4 and IL-13 signaling pathways and significantly improve moderate to severe atopic dermatitis.It is a human monoclonal antibo...